Zollinger‑Ellison Syndrome (Ulcer Pain)

What is Zollinger‑Ellison Syndrome (Ulcer Pain)?

Zollinger‑Ellison Syndrome (ZES) is a rare disorder in which one or more tumors called gastrinomas form in the pancreas or the upper part of the small intestine (duodenum). These tumors secrete excessive amounts of the hormone gastrin, which dramatically stimulates the stomach lining to produce acid. The resulting hyper‑acidic environment leads to severe, recurrent ulcer pain, often in the upper abdomen, and can cause multiple peptic ulcers that are resistant to standard therapy.

Although ZES accounts for less than 1 % of all peptic‑ulcer disease, it is clinically important because the ulcer pain is usually more intense, occurs at atypical locations (e.g., beyond the duodenum), and the underlying tumor can be malignant in up to 25‑50 % of cases. Early recognition can prevent complications such as bleeding, perforation, or metastasis.

Common Causes

While the primary cause of ZES is a gastrin‑secreting tumor, several conditions can produce similar ulcer‑pain patterns by increasing gastric acidity or impairing mucosal defenses. The list below includes the most frequent contributors that clinicians consider when evaluating a patient with persistent or atypical ulcer pain.

• Gastrinomas (Zollinger‑Ellison Syndrome) – the defining cause.
• Multiple Endocrine Neoplasia type 1 (MEN‑1) – an inherited syndrome that often includes gastrinomas.
• Helicobacter pylori infection – a common bacterial cause of peptic ulcers.
• Non‑steroidal anti‑inflammatory drug (NSAID) use – impairs prostaglandin protection of the gut lining.
• Chronic use of proton‑pump inhibitor (PPI) rebound hyper‑acidity – after abrupt discontinuation.
• Hyperparathyroidism – part of MEN‑1, can exacerbate acid production.
• Stress‑related mucosal disease (e.g., severe trauma, ICU patients) – increases acid secretion and reduces blood flow.
• Rare neuroendocrine tumors of the duodenum or stomach – may secrete gastrin or other acid‑stimulating peptides.
• Helicobacter heilmannii infection – less common than H. pylori but also ulcerogenic.
• Idiopathic hypergastrinemia – elevated gastrin levels without an identifiable tumor.

Associated Symptoms

Because the excessive acid attacks the entire upper gastrointestinal (GI) tract, patients with ZES often experience a constellation of symptoms beyond simple epigastric pain.

• Burning or gnawing epigastric pain – classically described as “ulcer pain.”
• Heartburn and acid reflux – due to high gastric acidity spilling into the esophagus.
• Frequent watery diarrhea – acid inactivates pancreatic enzymes, leading to malabsorption.
• Weight loss – from malabsorption and decreased intake due to pain.
• Nausea or vomiting – sometimes with food intolerance.
• Upper‑GI bleeding – melena or hematemesis when ulcers erode vessels.
• Perforation signs – sudden severe pain, rigidity, and guarding.
• Fatigue or anemia – chronic blood loss.
• Skin changes (in MEN‑1) – hyperpigmentation, pituitary lesions, or parathyroid adenomas.

When to See a Doctor

Persistent or worsening ulcer pain warrants prompt medical evaluation, especially when any of the following are present:

• Pain that does not improve with usual antacids or over‑the‑counter PPIs.
• Recurrent ulcers despite standard therapy.
• Unexplained weight loss, persistent diarrhea, or vomiting.
• Signs of bleeding – black tarry stools, vomiting blood, or sudden weakness.
• Family history of MEN‑1 or other endocrine tumors.
• Sudden onset of severe abdominal pain, especially if accompanied by fever or a rigid abdomen.

Early consultation can lead to timely diagnosis, prevent complications, and improve long‑term outcomes.

Diagnosis

Diagnosing ZES involves confirming hypergastrinemia, demonstrating acid hypersecretion, and locating the gastrinoma. The typical work‑up proceeds in stages:

1. Laboratory Tests

• Fasting serum gastrin level – values > 1000 pg/mL (or > 10‑times the upper limit) strongly suggest ZES, especially when the patient is off PPIs for 7–10 days.
• Secretin stimulation test – in ZES, gastrin levels paradoxically rise after IV secretin.
• Gastric pH measurement – a basal pH < 2 indicates acid hypersecretion.
• Basic metabolic panel – to assess electrolyte abnormalities from diarrhea.

2. Imaging Studies

• Endoscopic ultrasound (EUS) – high‑resolution view of pancreas and duodenum.
• Multiphasic contrast‑enhanced CT or MRI – to locate primary tumor and evaluate metastatic spread.
• Somatostatin receptor scintigraphy (Octreoscan) or ^68Ga-DOTATATE PET/CT – highly sensitive for neuroendocrine tumors.

3. Endoscopy

• Upper endoscopy (EGD) – visualizes ulcer size, number, and location; biopsies rule out malignancy and H. pylori infection.

4. Genetic Testing

• When MEN‑1 is suspected, testing for MEN1 gene mutations guides surveillance for other endocrine tumors.

Guidelines from the NIH and Mayo Clinic recommend a combination of fasting gastrin level, secretin test, and imaging to confirm the diagnosis (Mayo Clinic, 2023).¹

Treatment Options

Treatment aims to control acid production, treat or remove the gastrinoma, and manage symptoms.

Medical Management

• High‑dose proton‑pump inhibitors (PPIs) – the cornerstone of therapy; doses up to 80 mg of omeprazole daily are often required to normalize gastric pH.
• H2‑receptor antagonists – can be added for breakthrough symptoms.
• Octreotide or Lanreotide (somatostatin analogues) – suppress gastrin secretion and may shrink tumor size.
• Antibiotic eradication of H. pylori – if infection is present, standard triple or quadruple therapy.
• Hydration and electrolyte replacement – especially in patients with chronic diarrhea.

Surgical Options

• Localized tumor resection – preferred when the gastrinoma is solitary and resectable; can be pancreaticoduodenectomy or enucleation.
• Debulking surgery – for metastatic disease, to reduce tumor burden and improve symptoms.
• Liver-directed therapies (e.g., radiofrequency ablation) – when hepatic metastases are present.

Targeted Therapies & Clinical Trials

• Everolimus or Sunitinib – approved for progressive, unresectable pancreatic neuroendocrine tumors.
• Peptide receptor radionuclide therapy (PRRT) – uses radiolabeled somatostatin analogues for metastatic disease.

Lifestyle & Home Care

• Take PPIs exactly as prescribed; don’t miss doses.
• Avoid NSAIDs, aspirin, and other ulcer‑aggravating drugs.
• Eat small, frequent meals and limit foods that trigger reflux (citrus, coffee, chocolate, spicy foods).
• Stay hydrated; oral rehydration solutions can offset diarrhea‑related fluid loss.
• Maintain a healthy weight and avoid smoking, which impairs mucosal healing.

Prevention Tips

Because ZES is typically tumor‑driven, true primary prevention is limited. However, patients can reduce the risk of ulcer complications and support overall gut health:

• Screen for and treat H. pylori infection early, especially if you have a family history of ulcers.
• Limit or avoid chronic NSAID use; consider acetaminophen for pain when appropriate.
• Adopt a balanced diet rich in fiber, fruits, and vegetables to promote mucosal integrity.
• Quit smoking and limit alcohol intake, both of which increase gastric acid secretion.
• If you have MEN‑1 or a known gastrinoma, adhere to regular surveillance imaging and labs as recommended by your endocrinologist.

Emergency Warning Signs

**References**

1. Mayo Clinic. “Zollinger‑Ellison syndrome.” Updated 2023. https://www.mayoclinic.org
2. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). “Zollinger‑Ellison syndrome.” 2022. https://www.niddk.nih.gov
3. American College of Gastroenterology. “Guideline for the Management of Peptic Ulcer Disease.” 2022. https://gi.org
4. World Health Organization. “WHO classification of tumours of the endocrine organs.” 2021.
5. Cleveland Clinic. “Gastrinoma (Zollinger‑Ellison Syndrome) Treatment.” 2023. https://my.clevelandclinic.org